pharma · Epilepsy · Allergic Reaction · AQST
Aquestive Therapeutics
Aquestive Therapeutics clinical programs — 9 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- Vancouver, CA
- Founded
- 2009
- Employees
- 75
- Programs
- 9
- Drugs
- 9
- Patents
- 17
Aquestive Therapeutics projects
9 ClinicalTrials.gov programs sponsored by Aquestive Therapeutics.
Aquestive Therapeutics has 9 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
42-1703
Aquestive Therapeutics
Epilepsy
1 trial -
DESF
Aquestive Therapeutics
Allergic Reaction
1 trial -
Diazepam Buccal Film
Aquestive Therapeutics
Epilepsy
2 trials -
Diazepam Buccal Film 12.5 mg
Aquestive Therapeutics
Epilepsy
1 trial -
Ondansetron (ODFS)
Aquestive Therapeutics
Nausea and Vomiting, Postoperative
1 trial -
Riluzole Oral Soluble Film
Aquestive Therapeutics
ALS
1 trial -
Riluzole Oral Soluble film (ROSF) 50 mg
Aquestive Therapeutics
Amyotrophic Lateral Sclerosis
1 trial -
Ondansetron (ODFS)
Aquestive Therapeutics
Healthy
1 trial -
Ondansetron 8 mg ODFS without water
Aquestive Therapeutics
Healthy Participants
1 trial
Frequently asked questions
How many clinical projects does Aquestive Therapeutics have?
9 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.